Blood Transfusion (Limitation of Liability) Act 1986

Key definitions and recurring legal constructs in the Act create the operating concepts that determine rights and duties.

• Relevant virus and disease: The Act uses a narrow biological focus. "Relevant virus" is defined as HTLV III and the disease is "the disease known as Acquired Immune Deficiency Syndrome" (s 3). This biological scope frames what transmissions are covered by the limitation in section 5.
• Approved/approval: The single procedural lever for the Act is approval by "the Secretary of the Department, by instrument in writing" (s 3). "Approved" attaches to testing procedures, manners of certification, approved forms for declarations, approved procedures for deriving and certifying blood products, and approved requirements for imports (see s 3 and the repeated use of "approved" in s 4). The Act therefore delegates essential normative detail to instruments made under the Secretary's approval power.
• Authorised supplier: A closed list with an open tail. The Australian Red Cross Society and the Commonwealth Serum Laboratories Commission are explicitly authorised suppliers (s 3). The Secretary may "approve" any other person to become an authorised supplier (s 3). Authorised supplier status is consequential because section 4 imposes duties only when "an authorised supplier takes, or proposes to take, blood" for transfusion or derivation (s 4(1)), and section 5(3) conditions immunity on observing Act-imposed requirements.
• Certified blood and certified blood product: Certification is a statutory status that arises where an authorised supplier carries out approved testing and certifies, in an approved manner, that blood or blood products are free from the relevant virus (s 4(1)(b),(d); s 4(2),(3)). The Act cross-references "certified" to these certification procedures (s 3).
• Donor declaration: Donors must sign a declaration in an approved form "not more than 12 hours previously" before blood is taken (s 4(1)(a)). False or misleading statements in that declaration are a criminal offence (s 7) and disqualify the maker from relying on the immunity (s 5(2)).
• Approved testing procedure: The authorised supplier "shall cause an approved testing procedure to be carried out" as soon as practicable after taking the blood (s 4(1)(b)). The Act does not itself specify technical testing standards; it imports them by reference to whatever the Secretary approves.
• Disposal and certification in an approved manner: Where tests detect the relevant virus, blood and derived products must be disposed of "in an approved manner" (s 4(1)(c)). Where tests do not indicate the presence of the relevant virus, the authorised supplier may certify the blood "in an approved manner" (s 4(1)(d)). The method of disposal and form of certification are therefore delegated to Secretaryly approval.
• Importation: Section 4(3) allows certification of blood or products imported from another State or Territory if (a) the supplying jurisdiction confers substantially similar immunities and (b) the authorised supplier complies with any approved requirements for such imports. Section 5(5) conversely removes immunity where a person is in breach of a requirement imposed by the supplying State or Territory law under which similar immunity was to be conferred.
• Emergency transfusion exception: Section 6 creates a limited pathway by which transfusion of uncertified blood may be treated as if it were certified for the purposes of section 5, but only where a donor declaration exists (s 6(b)) and immediately before transfusion at least two medical practitioners opine that the recipient is likely to die unless the blood/product is administered before sufficient certified supply could be reasonably expected (s 6(c)). The section requires the two-doctor opinion "immediately before" the transfusion.
• Immunity exceptions: Section 5(2)-(6) lists disqualifying circumstances: false declarations (s 5(2)); failure by an authorised supplier to observe a requirement imposed by or under the Act (s 5(3)); failure by an employee or unpaid worker to observe a requirement applicable to their duties (s 5(4)); failure to comply with the supplying State/Territory law in relation to imports (s 5(5)); reasonable cause to suspect contamination (s 5(6)(a)); negligence or wilful misconduct exposing the blood/product to contamination (s 5(6)(b)).
• Criminal offence for false donor statements: Section 7 creates an offence for knowingly making a false or misleading statement in a declaration made under sections 4(1)(a) or 6(b), with a maximum fine up to 100 penalty units or imprisonment up to two years.

These constructs together shape the statutory risk allocation. Certification is a procedural status created by a combination of donor declarations, approved testing, and Secretaryly-approved manners of certification and disposal, and the statutory immunity in section 5 is contingent on compliance with these delegated procedural rules and on the absence of certain subjective and objective failings (knowledge, reasonable suspicion, negligence or wilful misconduct).

The Act sets duties and confers protections across four principal groups: donors, authorised suppliers (and their employees), medical practitioners performing transfusions, and persons involved in importation of blood and blood products into Tasmania from other Australian States/Territories. Each group's position is defined by statutory duties, affirmative compliance steps, and routes to or away from the statutory immunity.

• Donors: A person from whom blood is taken for transfusion or derivation must sign a declaration in an approved form not more than 12 hours before the taking of blood (s 4(1)(a)). Donors who knowingly make false or misleading statements in that declaration commit a criminal offence (s 7) and are excluded from immunity in relation to blood taken following that declaration (s 5(2)). Donors who sign truthful declarations therefore enable downstream certification processes; donors who make false statements both risk criminal sanction and negate immunity for the specific blood in question.
• Authorised suppliers: The Act explicitly identifies the Australian Red Cross Society and the Commonwealth Serum Laboratories Commission as authorised suppliers (s 3). The Secretary may approve other persons to be authorised suppliers (s 3). Authorised suppliers that take or propose to take blood have operational duties: obtain donor declarations (s 4(1)(a)), cause approved testing procedures to be carried out promptly (s 4(1)(b)), dispose of infected blood in an approved manner where tests indicate presence of the relevant virus (s 4(1)(c)), and may certify blood free from the relevant virus where tests are negative (s 4(1)(d)). Authorised suppliers may certify derived blood products where each portion is certified (s 4(2)). An authorised supplier importing blood from another State or Territory may certify that blood where that supplying jurisdiction confers substantially similar immunities and the authorised supplier complies with any approved import requirements (s 4(3)). Crucially, an authorised supplier loses the Act's protection where it "fails to observe a requirement imposed on it by or under this Act in relation to the blood or blood product" (s 5(3)), creating strong incentives for authorised suppliers to comply with statutory and Secretaryally approved rules.
• Employees and unpaid workers of authorised suppliers: Section 5(4) explicitly conditions the immunity of employees and those working without payment upon their observation of requirements imposed on the authorised supplier that are applicable to their duties. If an employee fails to observe such a requirement, the employee is not entitled to the protection of the immunity in relation to the blood or blood product concerned.
• Medical practitioners: Medical practitioners feature in the emergency-transfusion pathway. For an emergency transfusion of uncertified blood to be treated as if certified, at least two medical practitioners must be of the opinion immediately before transfusion that the patient is likely to die unless the blood or product is administered before sufficient certified supply could reasonably be expected to become available (s 6(c)). This places on medical practitioners the factual judgement that enables the exception in s 6; their contemporaneous opinions are prerequisites to invoking the statutory immunity where uncertified blood is used.
• Importers and persons dealing with interstate blood and products: Section 4(3) and section 5(5) together create a framework for imported blood and products. An authorised supplier who imports blood or blood products into Tasmania may certify them if the supplying State or Territory confers substantially similar immunities and the authorised supplier complies with any approved requirements (s 4(3)). Conversely, section 5(5) removes immunity where a person is in breach of a requirement imposed pursuant to the law of the supplying State or Territory that was relevant to conferring similar immunity. This exposes importers to two overlapping regimes: complying with the Act's approved requirements and ensuring compliance with supplying-jurisdiction laws.
• Recipients of transfusions: While the Act is primarily concerned with limitation of liability rather than affirmative duties on recipients, recipients are indirectly affected. The statutory immunity in s 5 reduces the available civil and criminal causes of action against persons involved in certified transfusion-related transmissions, and the emergency exception in s 6 provides a route for use of uncertified blood in life-threatening cases without exposing transfusing persons to liability, if its conditions are met. The Act does not create private rights or remedies for recipients; rather it modifies the existing civil or criminal exposure of suppliers and transfusing persons.

Across these groups the Act distributes obligations (donor declarations, approved testing, certification, disposal, compliance with approved import requirements, contemporaneous medical opinions in emergencies) and conditional protections (statutory immunity subject to exceptions). A dominant structural feature is delegation of the detailed technical, documentary and procedural rules to Secretaryly approval instruments and the requirement that authorised suppliers and covered persons observe requirements "imposed on ... by or under this Act" to retain immunity (s 5(3)-(4)).

The Act's operative rights and duties are sparse in number but specific in effect. Below are the principal duties imposed on named actors and the key rights (notably the immunity) the Act creates, with section references.

Duties

• Donor declaration duty: A donor must, if asked, sign a declaration in an approved form not more than 12 hours before blood is taken for transfusion or derivation (s 4(1)(a)). This is a precondition for authorised suppliers to proceed with testing and potential certification.
• Approved testing duty on authorised suppliers: An authorised supplier must cause an approved testing procedure to be carried out as soon as practicable after taking blood (s 4(1)(b)). This is a mandatory operational duty; it triggers the subsequent certification/disposal options in s 4.
• Disposal duty on authorised suppliers: If approved testing indicates presence of the relevant virus, the authorised supplier "shall dispose of the blood and any blood product derived from the blood in an approved manner" (s 4(1)(c)). The mode of disposal is delegated to Secretary approval.
• Certification power and duty: Where approved testing does not indicate the virus, the authorised supplier "may, in an approved manner, certify that the blood is free from the relevant virus" (s 4(1)(d)). The authorised supplier similarly may certify a blood product derived from certified portions (s 4(2)). The power to certify is thus discretionary but governed by approved procedures.
• Duty to prevent use when reasonably suspecting contamination: An authorised supplier who has reasonable cause to suspect that blood or a blood product it supplied may be contaminated shall take all reasonable steps to ensure that it is not used for transfusion or derivation for transfusion (s 4(4)). This is an affirmative risk-mitigation duty.
• Duties for imports: An authorised supplier importing blood or blood product from another State/Territory must ensure that substantially similar immunities are conferred by the supplying jurisdiction and must comply with any approved requirements for such imports to be able to certify (s 4(3)).
• Emergency physician opinion duty: For emergency use of uncertified blood to be covered, two medical practitioners must form the required opinion immediately before transfusion that immediate administration is necessary to avoid death (s 6(c)). The opinion requirement is a contemporaneous factual gate.

Rights and protections

• Statutory immunity: Section 5(1) provides that "subject to this section", no civil or criminal liability attaches to any person in respect of transmission to another of the relevant virus or AIDS by reason of transfusion of certified blood or a certified blood product. This is the Act's central right.
• Conditional certification right: An authorised supplier may certify blood or blood products as free of the relevant virus where testing procedures and approved procedures are complied with (s 4(1)(d), s 4(2)). Certification is the procedural instrument that creates the right to statutory immunity for subsequent transmission events.
• Emergency transfusion parity right: Under the exacting conditions of section 6 the Act treats uncertified blood as certified for section 5 purposes, thereby extending the immunity to transfusing persons in narrowly defined life-threatening scenarios.

Disqualifications, which operate as negative rights or duties by exclusion

• False declaration exclusion: A donor who knowingly makes a false declaration under s 4(1)(a) or s 6(b) is not entitled to the protection of section 5 in relation to the blood in question (s 5(2)). Separately, making such a false or misleading statement is a criminal offence under s 7.
• Authorised supplier non-compliance: An authorised supplier that fails to observe a requirement imposed on it by or under this Act loses the protection of section 5 (s 5(3)). This creates a strong compliance incentive on suppliers to ensure adherence to all statutory or subordinate requirements.
• Employee non-compliance: A person who is an employee or unpaid worker of an authorised supplier loses immunity under section 5 if that person fails to observe a requirement imposed on the authorised supplier that is applicable to the employee’s duties (s 5(4)). This places individual responsibility on employees to follow supplier-imposed requirements that are statutory in origin.
• Import compliance failure: A person is not entitled to immunity in relation to imported blood or products if that person is in breach of a supplying State/Territory requirement under which an immunity similar to section 5 would have been conferred (s 5(5)).
• Reasonable suspicion or negligence/wilful misconduct: Section 5(6)(a) removes immunity where a person has reasonable cause to suspect contamination; section 5(6)(b) removes immunity where the person, or an employee/unpaid worker, was guilty of negligence or wilful misconduct that exposed the blood or product to contamination.

Criminal offence and penalty

• False donor declaration: Section 7 creates an offence for knowingly making a false or misleading statement in a declaration required by section 4(1)(a) or 6(b). The statute sets a maximum penalty of a fine not exceeding 100 penalty units or imprisonment not exceeding two years. The Act uses the penalty unit construct but does not define its monetary value within the text provided; the enforcement mechanism for that penalty is not specified in the Act itself.

Process and discretion

• Secretary approvals: The Act repeatedly relies on approvals given "by the Secretary of the Department, by instrument in writing" (s 3). The Secretary's approvals determine who is an authorised supplier and what testing procedures, forms, manners of certification and disposal, and import requirements are acceptable. The Act does not in this text name the Department, the criteria for approval, or channels for review of approvals, leaving a significant portion of substantive detail to subordinate instruments.

Together, these duties and rights establish a compliance-based pathway to statutory immunity for persons involved in the collection, testing, certification, storage, importation and transfusion of blood and blood products where the relevant virus is HTLV III.

The Act provides two distinct enforcement mechanisms: statutory immunities that adjust civil and criminal exposure, and a standalone criminal offence for false or misleading donor declarations. The text itself prescribes no administrative penalty framework, no licensing fees, and no civil remedies created by the statute; rather, it alters the liability landscape and creates one criminal sanction.

Criminal penalty for false declarations

• Section 7 establishes a criminal offence for a person who knowingly makes a false or misleading statement in a declaration signed for the purposes of section 4(1)(a) or section 6(b). The section sets maximum penalties: a fine not exceeding 100 penalty units or imprisonment for a term not exceeding two years. The Act states the maximum but does not specify enforcement agencies or prosecutorial discretion within the text; ordinary criminal processes would follow for prosecution of this offence under prosecutorial authority in the jurisdiction.

Scope and operation of immunity as an enforcement/relief mechanism

• Section 5(1) provides the Act's principal enforcement effect by removing both civil and criminal liability for transmission arising from transfusion of certified blood or certified blood products, subject to exceptions in the section. The immunity is not a positive administrative sanction; it is a shield that defendants would assert in civil litigation or criminal proceedings to avoid liability. The availability of the shield depends on compliance with the Act's conditions and absence of disqualifying conduct listed in sections 5(2)-(6).
• Because the immunity cuts across civil and criminal liability, it changes potential exposure in negligence or intentional tort suits and in criminal prosecutions related to transmission. The Act does not set evidentiary standards for what constitutes certification, but certification itself is procedurally defined by approved testing and approved manner of certification (see s 4). In disputes, evidence about compliance with approved procedures and whether approvals were properly obtained will be decisive.

Exceptions and disqualifying conduct that create enforcement risk

• False declarations exclude immunity (s 5(2)) and are separately criminalised (s 7).
• Failure by an authorised supplier to observe a requirement "imposed on it by or under this Act" removes immunity (s 5(3)). That allows regulatory or prosecutorial actors, or private litigants, to attack claimed immunity by proving non‑observance of statutory obligations.
• Employees and unpaid workers can lose immunity where they fail to observe a requirement applicable to their duties (s 5(4)). This creates direct personal exposure for operational staff.
• A person is not protected if they have reasonable cause to suspect contamination (s 5(6)(a)). This subjective-objective standard may prove contested in litigation; it introduces a factual enquiry that can be used by claimants to defeat immunity.
• Negligence or wilful misconduct that exposed the blood/product to contamination removes immunity (s 5(6)(b)). This reintroduces classic liability concepts; the Act narrows immunity but preserves liability where the conduct of an actor or an employee is culpable.

Administrative enforcement, approvals and potential review

• The Act centralises approval power in the Secretary (s 3). The Secretary's instruments in writing will set the approved forms, testing procedures, and manners of certification and disposal. Because these approvals determine compliance, the Secretary's instruments are effectively the operational standards against which compliance is judged. The Act itself does not specify internal administrative review, appeal rights, or public reporting obligations for those approvals; those mechanisms, if any, would exist in subordinate instruments or in the administrative law framework external to the Act.

Limitations in the Act as to enforcement architecture

• The Act does not create a statutory inspectorate, does not prescribe inspection or auditing powers, and does not spell out record-keeping obligations or a regime of administrative sanctions distinct from the immunity/disqualification scheme and the s 7 offence. The enforcement architecture is therefore largely reactive: prosecution of false declarations and litigation where immunity is contested on the listed grounds.
• The Act does not specify how certification is to be evidenced for court or prosecutorial purposes other than that certification be "in an approved manner" (s 4(1)(d), s 4(2), s 4(3)). In practice this will import documentary processes determined by the Secretary but those are not contained in the Act.

In short, the Act's enforcement effect is realised through the interplay of a protective statutory immunity subject to enumerated exceptions and a single criminal offence directed at false donor declarations. The operational details that determine compliance and hence the success of immunity claims are delegated to Secretaryly approvals, and the Act does not itself provide a broader administrative enforcement apparatus within its text.

The Act expressly cross-references and interacts with other legal instruments and jurisdictions in several places, and it leaves room for external legal requirements to displace or condition its protections.

Commonwealth Serum Laboratories Act 1961

• The Act identifies the Commonwealth Serum Laboratories Commission, established by the Commonwealth Serum Laboratories Act 1961 (Commonwealth), as an authorised supplier (s 3(b)). This is a direct point of interconnection; the status of that Commonwealth body is recognised within the Tasmanian statutory framework for authorised suppliers. The Act does not, within its text, define how Commonwealth law or Commonwealth regulatory practice will influence approval or certification apart from this recognition.

Interstate and Territory laws

• Section 4(3) permits an authorised supplier to certify blood or blood products imported into Tasmania from another State or Territory where "immunities substantially similar to those conferred by section 5 are conferred by a law of that State or Territory" and the authorised supplier complies with any approved requirements for the purposes of the subsection. This provision creates a condition precedent for interstate certification: both similarity of immunity in the supplying jurisdiction's law and compliance with any Secretary-approved import requirements.
• Section 5(5) complements this by denying the protection of section 5 where a person is in breach of, or has failed to comply with, a requirement imposed by the law of the supplying State or Territory "under which an immunity substantially similar to an immunity conferred by this section is, or, but for that breach or failure, would be, conferred upon him." Practically, this means that compliance with the supplying jurisdiction's legal requirements is a precondition to receiving the Act's immunity for imported material.
• The Act therefore envisages bilateral or multijurisdictional regulatory interplay: importers must satisfy both the supplying jurisdiction's law and the Tasmanian Secretary-approved import requirements. The Act does not, however, specify how to resolve conflicts between the supplying jurisdiction's law and Tasmanian approval requirements, nor does it outline recognition procedures beyond the "substantially similar immunities" test and compliance.

Administrative law and delegated instruments

• The Act delegates multiple matters to instruments "in writing" approved by the Secretary of the Department (s 3). These approvals will interact with the broader administrative law framework: the criteria for approval, the content of approved testing procedures and forms, and the manner of certification or disposal will be given legal effect by the Secretary's instruments. The Act itself does not prescribe the administrative processes for making, publishing, or reviewing those instruments, so the Act will interact with any general administrative statute or rules in force in the jurisdiction that govern administrative decision-making, review, or judicial oversight of executive acts. The Act’s reliance on Secretary approvals therefore embeds administrative law considerations into core operational compliance.
• The definition of "approved" as approval by the Secretary suggests that subordinate lawful instruments, potentially including standards, protocols and forms, will be determinative for many compliance issues. The Act does not itself state whether those instruments will be disallowable legislative instruments, guidelines, or other forms of administrative instruments.

Civil and criminal liability regimes

• The Act modifies the landscape of civil and criminal liability by carving out statutorily-defined immunities for certified transfusions and certain emergency transfusions (s 5, s 6). It interacts with existing tort law and criminal statutes by changing whether civil or criminal liability "attaches" in specified factual circumstances; the Act does not create civil causes of action or new crimes beyond s 7, but it removes both civil and criminal liability as a matter of statutory immunity in defined cases. Therefore, it interacts with common law and other statutory liability regimes by narrowing available causes of action or criminal charges in the event the statutory preconditions are met.

Penalty framework elsewhere

• Section 7 uses the concept of "penalty units" in setting the maximum fine (100 penalty units). The monetary value of a penalty unit is not set within the Act; the Act therefore interacts with the jurisdiction's general statutory definition of "penalty unit" and any provisions that adjust the unit for inflation or other purposes. The Act does not itself supply the conversion or the enforcement machinery for penalty units; those exist in other statutory materials.

Absence of explicit interaction clauses

• The Act contains no express savings, non-derogation, or conflict resolution clauses that would, for example, state how it interacts with other Tasmanian health, public health, biosecurity, or criminal statutes. Interaction will be shaped by ordinary statutory interpretation principles and by the particular content of Secretary-approved instruments or external laws referenced by sections 4 and 5. This leaves open potential questions about overlap with statutes that regulate blood, public health, or clinical negligence that are not expressly mentioned in the Act.

Overall, the Act is designed to be used in a multi-actor, multi-jurisdictional environment and depends heavily on conformity with supplying jurisdictions and on Secretaryly subordinate approvals. Its protective immunities are expressly conditioned on compliance with other laws when dealing with imported material, and its delegated approvals will be the primary interface with technical and procedural standards set elsewhere.

The Act text provided contains explicit amendment notes and historical markers for several sections. The text itself shows the following amendments and applied dates where indicated in the in-text notes:

• Section 3: The definition section carries the note "[Section 3 Amended by No. 5 of 1990, s. 3 and Sched. 1]". This indicates that section 3 was amended by Act number 5 of 1990, section 3 and Schedule 1, though the supplied text does not detail the pre-amendment wording or the specific changes effected by that amending Act. The current text of s 3 includes the definitions of "approved", "authorised supplier", "blood product", "certified" (cross-referenced to s 4), "relevant virus" and "transfusion".
• Section 6: The heading carries two amendment notes. First "[Section 6 Amended by No. 2 of 1996, s. 87 and Sched. 7]" appears, showing an amendment by Act number 2 of 1996. Second, there is an amendment notation tied to the insertion of the two-medical‑practitioner requirement, marked "[Section 6 Amended by No. 3 of 2010, Sched. 1, Applied:01 Jul 2010]" with a link indicating the applied date of 1 July 2010. The effect in the current text is that section 6(c) requires not less than two medical practitioners to be of the opinion immediately before carrying out the transfusion that the patient is likely to die unless the blood/product is administered before sufficient certified supply could reasonably be expected to be available.
• Section 7: The heading includes the note "[Section 7 Amended by No. 43 of 1991, s. 5 and Sched. 1]". This identifies an amendment enacted by Act number 43 of 1991, section 5 and Schedule 1. The present text of section 7 prescribes the offence and maximum penalties for false or misleading donor declarations.

Other structural items

• Short title and commencement: Section 1 prescribes the short title as the Blood Transfusion (Limitation of Liability) Act 1985. Section 2 provides that the Act commenced on the day it received Royal Assent. The supplied text does not include the Royal Assent date as a separate line, but s 2 signals immediate commencement at Royal Assent.
• The Act includes links to versions and to other Acts (for example, the Commonwealth Serum Laboratories Act 1961 in s 3(b)) suggesting that it was enacted in a legal environment where inter-Act references were significant. The in-text amendment notes indicate that the Act has been subject to at least three later legislative changes (1990, 1991, 1996) and an applied amendment in 2010.

What is not supplied in the text

• The supplied text does not set out the precise content of the Secretary’s instruments of approval, so the amendments that put in place the Secretary's approval powers are visible but subordinate instruments or guidelines that implement and explain how approvals work are not provided here.
• The supplied text does not include the dates of each amending Act's assent, the exact words changed by the amending provisions, or any transitional or savings provisions that might have accompanied the amendments. It shows the presence of later amendments but not their legislative history or the policy material that accompanied them.

In sum, the Act originated in 1985 (short title) and has been amended at least in 1990, 1991, 1996 and by a change applied in 2010, according to the in-text amendment annotations. The amendments visibly affected the interpretation/definition section (s 3), the emergency transfusion provision (s 6), and the false statement offence (s 7). The precise content and legislative reasoning for those amendments are not contained in the supplied text; the text only records that those sections were amended by the indicated Acts.

The supplied statutory text contains no recorded litigation history, judicial interpretations, or cited cases. There are therefore no cases named in the Act text that can be reported here. Nonetheless, the statute’s text identifies a narrow set of legal questions that would be focal points in any litigation arising under the Act, namely:

• Meaning and sufficiency of "certified": The Act defines "certified" by cross-reference to the certification mechanisms in section 4(1)(d), (2) and (3) (s 3). Litigation would likely focus on whether an authorised supplier properly followed the Secretary-approved testing procedures and certified in the approved manner required by s 4. Disputes would turn on documentary and evidentiary proof of approved testing having been carried out "as soon as practicable" (s 4(1)(b)) and that certification was performed "in an approved manner" (s 4(1)(d)). Courts would have to determine whether the certification instruments and clinical testing conformed to the Secretary's approvals.
• Meaning of "approved" and scope of Secretary approvals: The Act delegates significant operational detail to approvals given by "the Secretary of the Department, by instrument in writing" (s 3). Litigation would likely probe the legal effect and validity of those instruments, whether they meet any applicable statutory or administrative law requirements, whether they were properly applied to particular facts, and whether failure to comply with a specific approval instrument occurred, engaging s 5(3) and s 5(4).
• "Reasonable cause to suspect" contamination: Section 5(6)(a) removes immunity where a person has "reasonable cause to suspect" contamination. Litigation would focus on the objective standard applied to that phrase: when did a person have reasonable cause, what steps should have been taken, and whether the person took "all reasonable steps" required by s 4(4) when suspicion arose. Factual findings about knowledge, information available, and contemporaneous practices would be central.
• Negligence and wilful misconduct: Section 5(6)(b) denies immunity where someone "was guilty of any negligence or wilful misconduct that exposed, or was likely to expose, the blood or blood product to contamination". Expect disputes about what standard of care applied to collection, storage, testing and handling operations, and whether conduct met the statutory threshold of negligence or wilful misconduct.
• Application of emergency exception: Section 6 permits uncertified blood to be treated as certified where an authorised donor declaration is present and where not less than two medical practitioners immediately before transfusion were of the specified life-or-death opinion. Litigation would examine whether the two‑doctor requirement was satisfied, when the opinions were formed (the section requires the opinion "immediately before" transfusion), and whether the factual circumstances met the "likely to die" threshold.
• Effect of false declaration and criminal offence: Section 5(2) excludes immunity in the case of a knowingly false declaration; section 7 creates the criminal offence. Litigation and prosecution would investigate mens rea (knowledge), the content of the declared statements, and the temporal link between declaration and subsequent use of blood (the declaration must have been signed not more than 12 hours before taking the blood under s 4(1)(a)).
• Imports and cross-jurisdictional compliance: Sections 4(3) and 5(5) raise questions about what constitutes "substantially similar" immunity in a supplying State/Territory and what it means to be in breach of the supplying jurisdiction's requirements. Litigation involving imported blood will require examining the supplying jurisdiction's law and whether the authorised supplier complied with any Secretary-approved requirements.

Absent recorded case law in the supplied text, these are the concrete areas where litigation is most likely to arise given the Act’s content. Any actual litigation would turn on evidence of what approvals existed, how testing and certification were performed and documented, the factual circumstances of any suspected contamination, and contemporaneous clinical judgements in emergency scenarios. Because the Act places central weight on Secretary-approved instruments, disputes about the validity, application and content of those instruments are likely to feature prominently in litigation, as would be ordinary civil and criminal proof issues concerning knowledge, negligence and wilful misconduct as referenced in s 5(2) and s 5(6).

The Act’s structure contains several operational and legal traps for donors, authorised suppliers, employees, medical practitioners and importers. These are concrete rules-based pitfalls that can have significant consequences because they either exclude immunity or criminalise conduct.

• Narrow donor timing window: Donor declarations must be signed "not more than 12 hours previously" before blood is taken (s 4(1)(a)). This is a tight, objectively timed requirement. Failure to obtain a declaration within that 12-hour window removes the procedural predicate for certification of blood derived from that donation and may complicate reliance on the section 6 emergency exception. Practitioners must track the temporal provenance of declarations carefully.
• Knowledge element for false declarations and exclusion from immunity: A donor who "knowingly" makes a false or misleading statement in the declaration both commits an offence under s 7 and is excluded from immunity in respect of the blood in question (s 5(2)). The combination of criminal exposure and civil/criminal exclusion from immunity means that a donor’s intentional dishonesty has both direct criminal consequences and downstream implications for liability allocation.
• Secretaryial approval as a single point of failure: The Act repeatedly depends on the Secretary’s written approvals for forms, testing procedures, manners of certification and disposal and import requirements (s 3 and s 4). If an authorised supplier or employee cannot show compliance with the Secretary‑approved instruments, section 5(3) and (4) will remove the immunity. The absence in the Act of detailed standards means that a failure to align operational practice to the Secretary's instrument, or an inability to produce the instrument in evidence, can negate immunity.
• Broad employee exposure: Employees and unpaid workers risk losing the immunity even if their employer-authorised supplier claims protection. Section 5(4) states an individual is not entitled to protection if that person "fails to observe a requirement imposed on the authorised supplier ... being a requirement applicable to the duties of that person". Employers therefore need to ensure that requirements imposed on the supplier are clearly communicated, allocated to specific job duties and documented; otherwise employees may become personally exposed.
• Unspecified "approved manner" and "approved testing procedure": The Act requires disposal "in an approved manner" if tests indicate the virus (s 4(1)(c)), and certification "in an approved manner" if tests are negative (s 4(1)(d)). What those manners are is left to the Secretary. Absent published, accessible instruments, authorised suppliers risk relying on idiosyncratic internal practices that a court might find inconsistent with the Secretary’s approvals, risking loss of immunity.
• "Reasonable cause to suspect" triggers affirmative obligation: Section 4(4) requires an authorised supplier that has reasonable cause to suspect contamination to "take all reasonable steps" to prevent use of the blood or blood product for transfusion. The subjective-objective hybrid "reasonable cause" phrase creates a fact-intensive inquiry that can be leveraged by plaintiffs to argue immunity should be denied under s 5(6)(a). Suppliers must adopt clear protocols to identify, document, and respond to potential contamination suspicions to minimise this risk.
• Emergency transfusion timing and the two‑doctor requirement: Section 6 requires that "immediately before the carrying out of the transfusion" at least two medical practitioners opine that delay would likely result in death. The "immediately before" phrasing makes contemporaneous documentation crucial. If those opinions cannot be shown as having been formed immediately before transfusion, immunity under s 6 and s 5 may not be available.
• Import compliance complexity: For imported blood, immunity depends both on the supplying State/Territory law conferring "substantially similar" immunities and on compliance with any approved requirements for imports (s 4(3)). Section 5(5) removes immunity where there was breach of a supplying jurisdiction requirement. Importers must therefore not only ensure conformity with Tasmanian Secretary-approved import requirements but also assess and document the legal and factual environment in the supplying jurisdiction to demonstrate similarity of immunity and compliance.
• Vagueness of "the Department": The Act repeatedly uses the phrase "the Secretary of the Department" without naming a specific department in the supplied text (s 3). That creates administrative ambiguity: authorised suppliers will need clarity on which Secretary and Department exercise the approval power, and how to obtain the relevant instruments in writing. Delays or disputes about the appropriate administrative office may hinder compliance and certification.
• No explicit administrative enforcement or inspection powers in the Act: The statute sets out duties and immunity outcomes but does not specify inspection, auditing or record-keeping requirements in the text provided. The absence of explicit statutory inspection powers means that compliance may depend on the Secretary’s subordinate instruments or external administrative law mechanisms; failure to adopt rigorous internal record-keeping can make it difficult to prove compliance in litigation.
• Criminal penalties use "penalty units" without value stated: Section 7 prescribes a maximum fine of 100 penalty units but does not state the monetary value per penalty unit. Practitioners must consult the jurisdiction's penalty unit scale to calculate the monetary exposure for an offence under s 7.
• Disqualification is specific to the blood involved: Section 5(2) excludes a person who knowingly makes a false declaration from protection "in relation to the blood, or any blood product in any way derived from the blood" for which the declaration was made. The disqualification is therefore fact-specific to the relevant donation; however, the reach to "any blood product in any way derived" extends the disqualification beyond whole blood to derivative products sourced from that donation.
• Burden on evidence in subsequent proceedings: Because immunity turns on procedural compliance and the content of Secretary-approved instruments, parties asserting the immunity will need contemporaneous, documentary evidence (approved forms, test results, clear certification records, import compliance documentation, and contemporaneous medical opinions in emergencies) to succeed. Lack of documentation can convert an otherwise lawful process into a litigation exposure risk.

These "gotchas" have operational significance: they concentrate compliance burdens on obtaining correct approvals, meeting tight timing windows, documenting medical opinions and test outcomes, maintaining clear internal instructions for employees, and ensuring that cross-jurisdictional sourcing aligns with supplying-jurisdiction requirements. Each gap or ambiguity in documentary compliance can negate the immunity that the Act otherwise grants.

Compliance under the Act requires a combination of procedural adherence, documentation, staff training, and inter‑jurisdictional due diligence. Below is a practical checklist, mapped to the statutory provisions, for authorised suppliers, employees, medical practitioners and importers who want to preserve the immunity in section 5 and avoid criminal liability under section 7.

For authorised suppliers (including the Australian Red Cross Society and Commonwealth Serum Laboratories Commission, and any other persons approved by the Secretary)

1. Secure and maintain "authorised supplier" status:

   • Ensure you are an authorised supplier as defined in s 3(b)-(c). If not already recognised, obtain written approval from the Secretary of the Department as required by s 3.

2. Use the Secretary-approved declaration form and ensure timing compliance:

   • Obtain donor declarations in the approved form and ensure each declaration was signed not more than 12 hours before the blood was taken (s 4(1)(a)). Log the exact date and time the declaration was signed and the time blood was taken.

3. Implement and evidence approved testing procedures:

   • Carry out the "approved testing procedure" required by s 4(1)(b) "as soon as practicable" after taking blood. Obtain and retain the Secretary's written approval for the testing procedure and create contemporaneous records (chain-of-custody, test kit batch numbers, test result timestamps). Document why the testing timing satisfied "as soon as practicable" if there is any delay.

4. Document certification and disposal in the approved manner:

   • Where tests do not indicate the relevant virus, certify the blood "in an approved manner" (s 4(1)(d)) and maintain records of the certificate showing the approved manner used. Where tests indicate presence of the virus, dispose of the blood and derived products "in an approved manner" (s 4(1)(c)) and retain written records showing compliance with the approved disposal process.

5. Establish protocols to act on reasonable suspicion:

   • Adopt clear internal procedures for recognising and responding to "reasonable cause to suspect" contamination. When any suspicion arises, take and record "all reasonable steps" to ensure the blood or product is not used for transfusion or derivation, as required by s 4(4). Keep contemporaneous logs of decisions, communications and steps taken.

6. Ensure employees know role‑specific requirements:

   • For each role, map the requirements "imposed on the authorised supplier by or under this Act" that are applicable to that employee’s duties, and implement training, checklists and supervision so that an individual is not considered to have failed to observe applicable requirements (s 5(4)). Keep evidence of training and role-specific procedures.

7. For derived products, ensure that each portion is certified:

   • When deriving blood products, ensure each portion of the material used is certified blood or a certified blood product before certifying the derived product (s 4(2)). Maintain traceability documentation linking derived product portions to their certified sources.

8. For imports, perform legal and documentary due diligence:

   • Before importing blood or blood products, confirm that the supplying State/Territory law confers immunities "substantially similar" to s 5 and obtain written evidence of such laws and of compliance with them. Comply with any Secretary-approved import requirements for the purposes of s 4(3). Retain supply-chain documents, certificates attesting to the supplying jurisdiction's statutory provisions, and proof of compliance with the supplying jurisdiction’s requirements to avoid the s 5(5) exclusion.

9. Maintain records to prove compliance:

   • Because sections 5(3) and 5(4) deny immunity where statutory requirements are not observed, keep a robust documentary system: approved declaration forms, test records, certificates, disposal logs, import documentation, Secretary approvals, internal SOPs and training records. Ensure records are time-stamped and non-repudiable wherever possible.

For employees and unpaid workers

1. Understand and follow requirements applicable to your duties:

   • Identify the supplier-level requirements that apply to your role and ensure you follow them. Under s 5(4), failure to observe such a requirement can remove immunity for the individual. Keep personal contemporaneous records where practicable.

2. Avoid knowingly false statements in declarations:

   • Donors and anyone who signs declarations must not knowingly make false or misleading statements; doing so is an offence (s 7) and brings exclusion from immunity (s 5(2)).

For medical practitioners performing transfusions

1. Emergency transfusion contemporaneous opinions:

   • If transfusing uncertified blood in an emergency and intending to rely on s 6, ensure not less than two medical practitioners are of the required opinion "immediately before" the transfusion that the patient is likely to die unless the blood/product is administered before sufficient certified supply could reasonably be expected to be available (s 6(c)). Document the names, clinical reasons, and timings of those opinions contemporaneously.

2. Be alert to reasonable suspicion and derivation‑related risks:

   • If a practitioner has reasonable cause to suspect contamination, communicate immediately with the authorised supplier and ensure the supply is not used, pursuant to s 4(4) and the immunity exceptions in s 5(6)(a)-(b).

For importers and persons acquiring interstate blood/products

1. Cross-jurisdictional compliance checklist:
   • Verify that the supplying State/Territory law confers